Federal contract award
75A50120C00001
ANTIBIOTIC FOR TREATMENT OF A BIOTHREAT INDICATION
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | BARDA - ASPR / DAAPPO / BARDA DCMA |
| NAICS | 541714 — Research and Development in Biotechnology (except Nanobiotechnology) |
| PSC | 6505 — Drugs and Biologicals |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | FIRM FIXED PRICE |
| Obligations | $265.3M |
| Current contract value | $265.3M |
| Potential contract value / ceiling | $303.8M |
| Start date | Dec 18, 2019 |
| Current end date | Dec 17, 2029 |
| Potential end date | Dec 17, 2029 |
| Latest award activity | Feb 20, 2026 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 14 of 14 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Feb 20, 2026 | P00013 | $0 | ANTIBIOTIC FOR TREATMENT OF A BIOTHREAT INDICATION |
| Feb 19, 2026 | P00012 | $17.5M | ANTIBIOTIC FOR TREATMENT OF A BIOTHREAT INDICATION |
| Mar 31, 2025 | P00011 | $5.0M | ANTIBIOTIC FOR TREATMENT OF A BIOTHREAT INDICATION |
| Feb 27, 2025 | P00010 | $0 | ANTIBIOTIC FOR TREATMENT OF A BIOTHREAT INDICATION |
| Dec 11, 2024 | P00009 | $0 | ANTIBIOTIC FOR TREATMENT OF A BIOTHREAT INDICATION |
| Jun 17, 2024 | P00008 | $0 | ANTIBIOTIC FOR TREATMENT OF A BIOTHREAT INDICATION |
| Feb 6, 2024 | P00007 | $17.5M | ANTIBIOTIC FOR TREATMENT OF A BIOTHREAT INDICATION |
| Nov 29, 2023 | P00006 | $808.0K | ANTIBIOTIC FOR TREATMENT OF A BIOTHREAT INDICATION |
| Jun 28, 2023 | P00005 | $0 | ANTIBIOTIC FOR TREATMENT OF A BIOTHREAT INDICATION |
| Dec 15, 2022 | P00004 | $36.4M | ANTIBIOTIC FOR TREATMENT OF A BIOTHREAT INDICATION |
| Sep 23, 2021 | P00003 | $31.6M | ANTIBIOTIC FOR TREATMENT OF A BIOTHREAT INDICATION |
| Jul 29, 2021 | P00002 | $43.5K | ANTIBIOTIC FOR TREATMENT OF A BIOTHREAT INDICATION |
| Mar 27, 2020 | P00001 | $97.2M | ANTIBIOTIC FOR TREATMENT OF A BIOTHREAT INDICATION |
| Dec 18, 2019 | 0 | $59.4M | ANTIBIOTIC FOR TREATMENT OF A BIOTHREAT INDICATION |
Estimated positioning window
Dec 17, 2028 – Jun 17, 2029
50/100
Why this recompete signal
Contract timing and recorded acquisition signals at the time of calculation.
Stored score: 50/100. Available recorded signals: 45 points.
- Contract end 2029-12-17 (1142 days from calculation)
- +5 points
- 25 historical awards in this buyer and category group
- +15 points
- 14 recorded award transactions
- +10 points
- Latest award action: 2026-02-20
- +5 points
- Parent award identifier recorded
- +0 points
- Solicitation identifier recorded
- +10 points
- Linked official forecast
- +0 points
- Calculated on
- 2026-11-01 10:17:53.997580+00:00
The historical group combines buyer, NAICS, and PSC. Multiple awards in this group do not by themselves establish repeated competitions.
Rule-based research score; it does not measure your chance of winning.
This older calculation does not retain a complete reproducible breakdown. Missing or changed inputs are not assigned invented points: Original award-value bonus input.
Recompete score calculated Nov 1, 2026.
Research next steps
- Check the linked forecast or SAM for a confirmed solicitation and current timing.
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.